|
...food intake may also influence metabolic rate. These modulators could be useful in pharmaceutical compositions for the treatment of obesity. APD356, discovered by Arena, is a selective and orally available 5-HT2C receptor modulator covered by the patent. A 12-week, randomized, double-blind, dose-ranging Phase 2b clinical trial studying APD356 in obese patients...
NOTE: All illustrations and photos
have been removed from this article.
More articles from BIOTECH Patent News
Human Genome Sciences obtains United States patent., October 01, 2005
Human Genome Sciences obtains United States patent., October 01, 2005
University of California obtains United States patent., October 01, 2005
Nanogen announces patent for fluorescent detection of nucleic acid tar..., October 01, 2005
Oncolytics announces issuance of second Canadian patent - therapeutic ..., October 01, 2005
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
